Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.46 |
| ▸ | MTOR | P42345 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11855240 | 0.98 | HRH4 (0.51) | HRH4ALDH1A1TSHRMAPK1TDP1 | |
| SCHEMBL11848455 | 0.87 | PIK3CA (0.58) | HRH4PIK3CAPIK3CDPIK3CGMTOR | |
| SCHEMBL2276716 | 0.87 | PIK3CA (0.62) | PIK3CAPIK3CDPIK3CGMTOR | |
| SCHEMBL17627939 | 0.83 | HRH4 (0.43) | HRH4PIK3CAPIK3CDPIK3CGMTOR | |
| SCHEMBL17627938 | 0.83 | HRH4 (0.43) | HRH4PIK3CAPIK3CDPIK3CGMTOR | |
| SCHEMBL22411579 | 0.78 | HRH4 (0.49) | HRH4ALDH1A1TSHRMAPK1TDP1 | |
| SCHEMBL11857645 | 0.77 | HTR3E (0.59) | HRH4ALDH1A1MAPK1TDP1MAPT | |
| SCHEMBL17628378 | 0.77 | PRKDC (0.44) | TSHRGFERPIK3CAMTORKMT2A | |
| SCHEMBL11857620 | 0.76 | PIK3CA (0.46) | HRH4PIK3CAPIK3CDPIK3CGMTOR | |
| SCHEMBL17628072 | 0.76 | CNR2 (0.47) | PIK3CAPIK3CDPIK3CGMTORKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290350-A | Heteroaryl and bisheteroaryl derivatives for the treatment of iron death-related disorders | 协同医药发展有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-113631535-B | Heteroaryl and bisheteroaryl derivatives for the treatment of iron death-related disorders | 协同医药发展有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230172940-A1 | METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230172940-A1 | METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20220144826-A1 | Heteroaromatic and Heterobicyclic Aromatic Derivatives for the Treatment of Ferroptosis-Related Disorders | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2022020150-A1 | METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2022-01-27 | — | — | WO | disclosed |
| EP-3938340-A1 | HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS | Collaborative Medicinal Development, LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-113631535-A | Heteroaryl and bis-heterocyclic aryl derivatives for the treatment of disorders associated with iron death | 协同医药发展有限公司 | 2021-11-09 | — | — | CN | disclosed |
| WO-2020185738-A1 | HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020185738-A1 | HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172940-A1 | METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS | GPX4, GPX1, AIFM2 | HRH4 4483/4885ALDH1A1 1337/4885TSHR 3486/4885 |
| US-20220144826-A1 | Heteroaromatic and Heterobicyclic Aromatic Derivatives for the Treatment of Ferroptosis-Related Disorders | AIFM2, FECH, SLC40A1 | HRH4 189/4885ALDH1A1 1127/4885TSHR 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.